LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) will host a press teleconference today, Wednesday, May 9th at 1:30 pm Pacific/4:30 pm Eastern to comment on the upcoming FDA Antiviral Products Advisory Committee hearing (scheduled for tomorrow, May 10th in Washington D.C.) on a new use for Gilead Sciences’ Inc.’s HIV/AIDS treatment drug Truvada as a pre-exposure prophylaxis (PrEP) or HIV prevention pill. AIDS Healthcare Foundation is opposed to approval by the U.S. Food and Drug Administration (FDA) for this new use contending that more study must be done to determine how the drug would be used in “real life” situations as the consequences of non-adherence and lowered condom use could be life-threatening.
